High levels of CSNK1E expression have been associated with a poor prognosis (i.e., shorter overall survival) in patients with ovarian cancer [23], but have been associated with a favorable prognosis in subsets of patients with breast cancer [24]. This evidence concerns the gene CSNK1E and breast carcinoma.